Sunitinib-Induced Cardiotoxicity Is Mediated by Off-Target Inhibition of AMP-Activated Protein Kinase
Authors:
- Risto KerkelaRKRisto Kerkela
- Kathleen C. WoulfeKWKathleen C. Woulfe
- Jean-Bernard DurandJDJean-Bernard Durand
- Ronald VagnozziRVRonald Vagnozzi
- David KramerDKDavid Kramer
- Tammy F. ChuTCTammy F. Chu
- Cara BeahmCBCara Beahm
- Ming Hui ChenMCMing Hui Chen
- Thomas ForceTFThomas Force
- 1 February 2009
- journal article
- Published by Wiley in Clinical and Translational Science
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer TherapeuticsCirculation, 2008
- Cardiotoxicity associated with the cancer therapeutic agent sunitinib malateAnnals of Oncology, 2008
- An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxicJournal of Clinical Investigation, 2007
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibThe Lancet, 2007
- Molecular basis for sunitinib efficacy and future clinical developmentNature Reviews Drug Discovery, 2007
- Possible molecular mechanisms involved in the toxicity of angiogenesis inhibitionNature Reviews Cancer, 2007
- Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibitionNature Reviews Cancer, 2007
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialThe Lancet, 2006
- Cardiotoxicity of the cancer therapeutic agent imatinib mesylateNature Medicine, 2006